Xpreza 200mg Tablet contains Azacitidine, a nucleoside metabolic inhibitor used primarily in the treatment of myelodysplastic syndromes (MDS) and certain types of acute myeloid leukemia (AML). Azacitidine acts by incorporating into DNA and RNA, leading to hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. This mechanism helps restore normal function and differentiation of blood cells, thereby improving hematologic parameters and reducing transfusion dependence. Xpreza is indicated for adult patients diagnosed with MDS, including refractory anemia with excess blasts, chronic myelomonocytic leukemia, and other related hematologic malignancies. The recommended dosage and administration should be determined by a healthcare professional based on the patient’s clinical condition, typically administered subcutaneously or intravenously in cycles. Common adverse effects include myelosuppression, nausea, vomiting, diarrhea, and injection site reactions. Regular monitoring of blood counts and organ function is essential during therapy to manage potential toxicities and adjust dosing accordingly. Xpreza should be used under strict medical supervision with appropriate supportive care to optimize therapeutic outcomes and minimize risks. It is contraindicated in patients with known hypersensitivity to azacitidine or any formulation components.